**Subject Enrollment/Screening Log**

**Study Title:**  
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Novostatin (Novitor) in Patients with Hypercholesterolemia

**Protocol Number:** NSP-002-2024  
**Study Duration:** March 2, 2024 – September 22, 2024  
**Sponsor:** Novitor Pharmaceuticals Inc.

**Screening Log Overview**

This log summarizes the screening and enrollment status for subjects recruited for the Novostatin Phase 2 trial. The log captures subject ID, screening date, informed consent date, demographic details, key eligibility parameters (e.g., BMI, LDL levels), eligibility status, and any relevant notes regarding inclusion or exclusion.

| **Subject ID** | **Screening Date** | **Informed Consent Date** | **Age (Years)** | **Sex** | **BMI (kg/m²)** | **LDL Cholesterol (mg/dL)** | **Eligibility Status** | **Reason for Exclusion (if applicable)** | **Notes** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| NS-101 | 02/24/2024 | 02/25/2024 | 52 | Female | 26.4 | 158 | Eligible | — | Met all inclusion criteria. |
| NS-102 | 02/26/2024 | 02/26/2024 | 56 | Male | 28.7 | 165 | Eligible | — | History of mild statin intolerance; acceptable. |
| NS-103 | 02/27/2024 | 02/28/2024 | 63 | Male | 36.2 | 172 | Ineligible | BMI > 35 kg/m² | Exceeded BMI criteria. |
| NS-104 | 02/28/2024 | 03/01/2024 | 48 | Female | 24.8 | 142 | Eligible | — | Meets all criteria. |
| NS-105 | 03/01/2024 | 03/01/2024 | 60 | Male | 29.5 | 180 | Eligible | — | Stable concomitant conditions. |
| NS-106 | 03/01/2024 | — | 55 | Female | 27.0 | 160 | Not Consented | No informed consent obtained | Declined participation. |
| NS-107 | 03/02/2024 | 03/02/2024 | 45 | Male | 30.0 | 155 | Eligible | — | Eligible for study. |
| NS-108 | 03/03/2024 | 03/03/2024 | 50 | Female | 28.0 | 160 | Eligible | — | Meets eligibility criteria. |
| NS-109 | 03/03/2024 | 03/03/2024 | 59 | Male | 31.0 | 170 | Eligible | — | No contraindications. |
| NS-110 | 03/04/2024 | 03/04/2024 | 62 | Female | 26.0 | 150 | Eligible | — | Meets study criteria. |
| NS-111 | 03/04/2024 | 03/04/2024 | 54 | Male | 29.0 | 165 | Eligible | — | Eligible. |
| NS-112 | 03/05/2024 | 03/05/2024 | 47 | Female | 25.0 | 140 | Eligible | — | Meets all inclusion criteria. |
| NS-113 | 03/05/2024 | 03/05/2024 | 68 | Male | 33.0 | 185 | Eligible | — | Eligible; close monitoring advised. |
| NS-114 | 03/06/2024 | 03/06/2024 | 70 | Female | 32.0 | 175 | Eligible | — | Meets criteria; age noted. |
| NS-115 | 03/06/2024 | 03/06/2024 | 52 | Male | 27.5 | 160 | Eligible | — | Eligible. |
| NS-116 | 03/07/2024 | 03/07/2024 | 58 | Female | 28.5 | 165 | Eligible | — | Eligible. |
| NS-117 | 03/07/2024 | 03/07/2024 | 49 | Male | 26.5 | 155 | Eligible | — | Eligible. |
| NS-118 | 03/08/2024 | 03/08/2024 | 61 | Female | 30.5 | 180 | Eligible | — | Eligible. |
| NS-119 | 03/08/2024 | 03/08/2024 | 66 | Male | 31.5 | 170 | Eligible | — | Eligible. |
| NS-120 | 03/09/2024 | 03/09/2024 | 53 | Female | 24.0 | 150 | Eligible | — | Eligible. |
| NS-121 | 03/09/2024 | 03/09/2024 | 57 | Male | 29.8 | 165 | Eligible | — | Eligible. |
| NS-122 | 03/10/2024 | 03/10/2024 | 50 | Female | 27.2 | 160 | Eligible | — | Eligible. |
| NS-123 | 03/10/2024 | 03/10/2024 | 62 | Male | 28.0 | 158 | Eligible | — | Eligible. |
| NS-124 | 03/11/2024 | 03/11/2024 | 63 | Female | 26.0 | 155 | Eligible | — | Eligible. |
| NS-125 | 03/11/2024 | 03/11/2024 | 47 | Male | 30.0 | 165 | Eligible | — | Eligible. |
| NS-126 | 03/12/2024 | 03/12/2024 | 59 | Female | 29.0 | 170 | Eligible | — | Eligible. |
| NS-127 | 03/12/2024 | 03/12/2024 | 64 | Male | 32.5 | 175 | Eligible | — | Eligible. |
| NS-128 | 03/13/2024 | 03/13/2024 | 51 | Female | 27.0 | 160 | Eligible | — | Eligible. |
| NS-129 | 03/13/2024 | 03/13/2024 | 55 | Male | 28.5 | 162 | Eligible | — | Eligible. |
| NS-130 | 03/14/2024 | 03/14/2024 | 60 | Female | 26.5 | 158 | Eligible | — | Eligible. |
| NS-131 | 03/14/2024 | 03/14/2024 | 53 | Male | 29.5 | 165 | Eligible | — | Eligible. |
| NS-132 | 03/15/2024 | 03/15/2024 | 68 | Female | 27.8 | 172 | Eligible | — | Eligible. |

**Summary**

* **Total Screened:** 32 subjects
* **Consented and Eligible:** 30 subjects
* **Excluded:** 1 subject (NS-103: BMI > 35 kg/m²)
* **Not Consented:** 1 subject (NS-106: No informed consent obtained)